A abiding abstraction on the capability of the biologic thalidomide as allotment of the analysis for assorted myeloma, one of the atomic curable cancers, showed bigger absolution ante in patients, appear a aggregation of University of Arkansas for Medical Sciences (UAMS) advisers led by internationally accepted myeloma researcher Bart Barlogie, M.D., Ph.D., in the latest affair of the New England Journal of Medicine.
Little Rock, AR -- A abiding abstraction on the capability of the biologic thalidomide as allotment of the analysis for assorted myeloma, one of the atomic curable cancers, showed bigger absolution ante in patients, appear a aggregation of Myeloma Institute for Research and Therapy (http://myeloma.uams.edu) advisers led by Bart Barlogie, M.D., Ph.D., in the latest affair of the New England Journal of Medicine.
The article “Thalidomide and Hematopoietic-Cell Transplantation for Multiple Myeloma” (http://content.nejm.org/cgi/content/full/354/10/1021?ijkey=NpKKiGnrNpOIE&keytype=ref&siteid=nejm) showed after-effects from the accession of thalidomide to a myeloma analysis dieting that included high-dose, melphalan-based chemotherapy in a ambience of bike borderline claret stem-cell transplants.
In the trial, involving 668 myeloma patients amid October 1998 and February 2004, those who accustomed thalidomide as allotment of their analysis had a college complete absolution amount and a above event-free, five-year adaptation amount (meaning there were no signs of backsliding in that time period) than those in a ascendancy group. However, thalidomide bootless to prolong all-embracing adaptation and was associated with adverse ancillary effects, including borderline neuropathy -- accident to the borderline afraid arrangement -- and deep-vein occlusion -- claret clots in the veins.
The article appears in the March 9, 2006, affair of the account medical journal.
Barlogie, advance researcher for the study, pioneered the use of thalidomide as a ameliorative abettor in alleviative assorted myeloma. Thalidomide was approved initially in the case of above ache because of its anti-angiogenic backdrop -- acceptation that it interferes with the claret accumulation to the bump beef and appropriately kills through an aberrant mechanism.
Further analysis has apparent that thalidomide exerts abounding potentially amiable anti-tumor effects, Barlogie said, including absolute bump corpuscle abolition and abeyance of tumor-host corpuscle alternation (“starve the berry by annihilative the soil”).
Lead UAMS advisers included:
- Barlogie, administrator of the Myeloma Institute for Research and Therapy (MIRT) (http://myeloma.uams.edu) at UAMS and a assistant of anesthetic and anatomy in the UAMS College of Medicine (http://www.uams.edu/com/) Guido Tricot, M.D., Ph.D., assistant of anesthetic and anatomy in the UAMS College of Medicine and administrator of analytic analysis for MIRT Elias Anaissie, M.D., assistant of anesthetic in the UAMS College of Medicine and administrator of admiring affliction for MIRT John Shaughnessy, Ph.D. assistant of anesthetic in the UAMS College of Medicine, administrator of basal analysis for MIRT, and administrator of the Lambert Laboratory of Myeloma Genetics for MIRT Frits van Rhee, M.D., Ph.D., accessory assistant of anesthetic in the UAMS College of Medicine Maurizio Zangari M.D., accessory assistant of anesthetic in the UAMS College of Medicine
Others complex in the analysis included Erik Rasmussen, M.S., and John Crowley, Ph.D., of Cancer Research and Biostatistics at the University of Washington, Seattle. (http://www.washington.edu)
Myeloma is a blazon of blight that involves claret beef – white claret beef that aftermath antibodies. When claret beef become cancerous, they carbon berserk and army out advantageous red and white claret cells, preventing them from angry infection and accustomed oxygen throughout the body. Bone abolition is a accepted appearance of myeloma. The cancerous beef aswell aftermath a blazon of protein that can could cause branch failure.
The boilerplate adaptation amount of a myeloma accommodating acclimated to be three years aloft diagnosis; acknowledgment to analysis adjourned in allotment by the National Cancer Institute (NCI - http://www.cancer.gov), the MIRT (http://myeloma.uams.edu) has continued the boilerplate adaptation amount of its patients to seven years and beyond.
The abstraction was adjourned by a activity affairs admission from the NCI, which in 2004 appear its third five-year face-lifting -- for about $18 actor -- of admission abutment for the MIRT. Those funds are appropriate for advancing translational analysis at the MIRT, the aboriginal ability in the apple created accurately to abstraction and amusement this attenuate anatomy of cancer.
About the University of Arkansas for Medical Sciences (UAMS):
UAMS is the state’s alone absolute bookish bloom center, with 5 colleges, a alum school, a medical center, 5 centers of arete and a statewide arrangement of bounded centers. UAMS has about 2,320 acceptance and 690 medical residents. It is one of the state’s better accessible administration with about 9,000 employees, including about 1,000 physicians who accommodate medical affliction to patients at UAMS, Arkansas Children’s Hospital and the VA Medical Center. UAMS and its affiliates accept an bread-and-butter appulse in Arkansas of $4.3 billion a year. UAMS centers of arete are the Arkansas Cancer Research Center (http://www.acrc.uams.edu), Harvey and Bernice Jones Eye Institute (http://www.uams.edu/jei), Donald W. Reynolds Institute on Aging( http://centeronaging.uams.edu), Myeloma Institute for Research and Therapy (http://myeloma.uams.edu) and Jackson T. Stephens Spine & Neurosciences Institute (http://www.uams.edu/stephensinstitute).
Contact:
Andrea Peel, communications manager
UAMS
501-686-8996
http://www.uams.edu | http://myeloma.uams.edu
# # #
